Affordable Access

Access to the full text

Nanotheranostics With the Combination of Improved Targeting, Therapeutic Effects, and Molecular Imaging

Authors
  • Peng, Shin-Lei1
  • Lai, Chih-Ho2
  • Chu, Pei-Yi3
  • Hsieh, Jer-Tsong4
  • Tseng, Yen-Chun5
  • Chiu, Shao-Chieh6
  • Lin, Yu-Hsin3, 7, 8
  • 1 Department of Biomedical Imaging and Radiological Science, China Medical University, Taichung
  • 2 Department of Microbiology and Immunology, Molecular Infectious Disease Research Center, Chang Gung University, Chang Gung Memorial Hospital, Taoyuan
  • 3 Faculty of Pharmacy, National Yang-Ming University, Taipei
  • 4 Department of Urology, University of Texas Southwestern Medical Center, Dallas, TX , (United States)
  • 5 Department of Biological Science and Technology, China Medical University, Taichung
  • 6 Center for Advanced Molecular Imaging and Translation, Chang Gung Memorial Hospital, Taoyuan
  • 7 Department of Medical Research, China Medical University Hospital, China Medical University, Taichung
  • 8 Institute of Biopharmaceutical Science, Department and Institute of Pharmacology, Center for Advanced Pharmaceutics and Drug Delivery Research, National Yang-Ming University, Taipei
Type
Published Article
Journal
Frontiers in Bioengineering and Biotechnology
Publisher
Frontiers Media SA
Publication Date
Sep 15, 2020
Volume
8
Identifiers
DOI: 10.3389/fbioe.2020.570490
Source
Frontiers
Keywords
Disciplines
  • Bioengineering and Biotechnology
  • Original Research
License
Green

Abstract

There is an increasing interest in the design of targeted carrier systems with combined therapeutic and diagnostic modalities. Therapeutic modalities targeting tumors with single ligand-based targeting nanocarriers are insufficient for proficient delivery and for targeting two different surface receptors that are overexpressed in cancer cells. Here, we evaluated an activated nanoparticle delivery system comprising fucoidan/hyaluronic acid to improve therapeutic efficacy. The system comprised polyethylene glycol-gelatin-encapsulated epigallocatechin gallate (EGCG), poly (D,L-lactide-co-glycolide; PLGA), and stable iron oxide nanoparticles (IOs). The latter enables targeting of prostate cancers in their molecular images. We demonstrate the transfer of nanoparticles and their entry into prostate cancer cells through ligand-specific recognition. This system may prove the benefits of drug delivery that enhances the inhibition of cell growth through apoptosis induction. Moreover, the improved targeting of nanotheranostics significantly suppressed orthotopic prostate tumor growth and more accurately targeted tumors compared with systemic combination therapy. In the presence of nanoparticles with iron oxides, the hypointensity of the prostate tumor was visualized on a T2-weignted magnetic resonance image. The diagnostic ability of this system was demonstrated by accumulating fluorescent nanoparticles in the prostate tumor from the in vivo imaging system, computed tomography. It is suggested that theranostic nanoparticles combined with a molecular imaging system can be a promising cancer therapy in the future.

Report this publication

Statistics

Seen <100 times